Managing Distress in Malignant Brain Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Ashlee Loughan, Ph.D
- Phone Number: 804-828-9815
- Email: ashlee.loughan@vcuhealth.org
Study Contact Backup
- Name: Jaclyn Sadicario, M.S.
- Email: sadicariojs@vcu.edu
Study Locations
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of brain metastasis (bMET) confirmed via medical records, radiography or histopathology
- At least 2 weeks post-surgical cranial resection or cranial biopsy (if applicable)
- Score > 20 on the TICS
- Report elevated depression (PHQ-9 score ≥ 10) OR death anxiety symptoms (DADDS score ≥ 15)
- Ability to read, speak, and understand English
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Major communication difficulties, which would prohibit psychotherapeutic interaction
- Inability to meet with interventionist via an electronic device for telehealth intervention sessions
- Inability to understand and provide informed consent
- Medical, psychological, or social condition that, in the opinion of the investigator, may increase the participant's risk
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CALM
CALM therapy will be provided via telehealth.
Participants will complete surveys (post-session, post-intervention, and 90-day follow-up) via secure email link.
Exit interviews will be conducted by phone
|
The CALM intervention includes 6 individual therapy sessions, each approximately 45-60 minutes in length, delivered over 3 months. Participants will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assess the Need for Adaptations to the CALM Intervention as Measured by the Applicability of the 4 CALM Domains
Time Frame: 4 Months
|
At the exit interview, participants will be asked to rate the applicability of the four CALM domains on a Likert Scale from 1 (not applicable) to 5 (very applicable).
The four CALM domains are as follows: Domain 1) represents symptom management and communication with healthcare providers, Domain 2) reflects changes in personal relationships, Domain 3) sense of meaning and purpose, and Domain 4) the future, hope and mortality.
Higher scores mean greater applicability.
|
4 Months
|
|
Feasibility of CALM Intervention in the Proof of Concept Project as Measured by the Rates of Participant Screening, Eligibility, and Consent.
Time Frame: 12 months
|
Determine how many patients consent to screening after referral to the program, how many patients are eligible for the program after being screened, and how many consent/enroll in the program if eligible.
|
12 months
|
|
Feasibility of CALM Intervention in the Proof of Concept Project as Measured by Attendance at CALM Sessions
Time Frame: 3 Months
|
Percent of sessions attended across all participants
|
3 Months
|
|
Feasibility of CALM Intervention in the Proof of Concept Project as Measured by the Rates of Post-session Assessment Completion
Time Frame: 3 Months
|
Percent of post-session surveys completed by participants immediately after the intervention
|
3 Months
|
|
Feasibility of CALM Intervention in the Proof of Concept Project as Measured by Post-intervention Assessment Completion
Time Frame: 3 Months
|
Percent of post-intervention surveys completed
|
3 Months
|
|
Benefit of Intervention in the Proof of Concept Project
Time Frame: 4 Months
|
Benefit will be assessed by participant responses to a question during the exit interview (e.g., Rate your overall benefit on a scale of 1-5).
|
4 Months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Repeated measures will assess changes within groups across time (pre-intervention, post-intervention, follow-up) in depression as measured by Patient Health Questionnaire - 9 Item (PHQ9) in the Proof of Concept project.
Time Frame: 6 months
|
Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report inventory measures depressive symptoms.
Derived from the validated full Patient Health Questionnaire, the PHQ-9 asks participants to rate frequency of their depressive symptoms over the previous two weeks using a 4-point Likert scale, ranging from 0 (not at all) to 3 (nearly every day).
Total scores (summing all items) range from 0-27.
Guidelines for score interpretation suggest: 0-5 minimal depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, and >20 severe depression.
|
6 months
|
|
Repeated measures will assess changes within groups across time (pre-intervention, post-intervention, follow-up) in suicidal ideation as measured by Patient Health Questionnaire - 9 Item (PHQ9) in the Proof of Concept project.
Time Frame: 6 months
|
Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report inventory measures depressive symptoms.
Derived from the validated full Patient Health Questionnaire, the PHQ-9 asks participants to rate frequency of their depressive symptoms over the previous two weeks using a 4-point Likert scale, ranging from 0 (not at all) to 3 (nearly every day).
Total scores (summing all items) range from 0-27.
Guidelines for score interpretation suggest: 0-5 minimal depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, and >20 severe depression.
The ninth item asks the participant to rate the frequency of the following: "Thoughts that you would be better off dead or of hurting yourself in some way" over the previous two weeks using a 4-point Likert scale, ranging from 0 (not at all) to 3 (nearly every day).
|
6 months
|
|
Repeated measures will assess changes within groups across time (pre-intervention, post-intervention, follow-up) in depression as measured by Patient Health Questionnaire - 9 Item (PHQ9) in the Pilot Trial.
Time Frame: 6 months
|
Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report inventory measures depressive symptoms.
Derived from the validated full Patient Health Questionnaire, the PHQ-9 asks participants to rate frequency of their depressive symptoms over the previous two weeks using a 4-point Likert scale, ranging from 0 (not at all) to 3 (nearly every day).
Total scores (summing all items) range from 0-27.
Guidelines for score interpretation suggest: 0-5 minimal depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, and >20 severe depression.
|
6 months
|
|
Repeated measures will assess changes within groups across time (pre-intervention, post-intervention, follow-up) in suicidal ideation as measured by Patient Health Questionnaire - 9 Item (PHQ9) in the Pilot Trial.
Time Frame: 6 months
|
Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report inventory measures depressive symptoms.
Derived from the validated full Patient Health Questionnaire, the PHQ-9 asks participants to rate frequency of their depressive symptoms over the previous two weeks using a 4-point Likert scale, ranging from 0 (not at all) to 3 (nearly every day).
Total scores (summing all items) range from 0-27.
Guidelines for score interpretation suggest: 0-5 minimal depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, and >20 severe depression.
The ninth item asks the participant to rate the frequency of the following: "Thoughts that you would be better off dead or of hurting yourself in some way" over the previous two weeks using a 4-point Likert scale, ranging from 0 (not at all) to 3 (nearly every day).
|
6 months
|
|
Repeated measures will assess changes within groups across time (pre-intervention, post-intervention, follow-up) in generalized anxiety as measured by the Generalized Anxiety Disorder - 7 Item (GAD7) in the proof of concept project.
Time Frame: 6 months
|
The GAD-7 assesses generalized anxiety symptoms within a two week period.
Participants rate how often they experienced various anxiety symptoms for seven items using a 4-point Likert scale: 0 (not at all) to 3 (nearly every day).
Scores are summed (range 0-21), with 0-4 indicating minimal anxiety, 5-9 mild anxiety, 10-14 moderate anxiety, and 15-21 severe anxiety.
|
6 months
|
|
Repeated measures will assess changes within groups across time (pre-intervention, post-intervention, follow-up) in generalized anxiety as measured by the Generalized Anxiety Disorder - 7 Item (GAD7) in the Pilot Trial
Time Frame: 6 months
|
The GAD-7 assesses generalized anxiety symptoms within a two week period.
Participants rate how often they experienced various anxiety symptoms for seven items using a 4-point Likert scale: 0 (not at all) to 3 (nearly every day).
Scores are summed (range 0-21), with 0-4 indicating minimal anxiety, 5-9 mild anxiety, 10-14 moderate anxiety, and 15-21 severe anxiety.
|
6 months
|
|
Repeated measures will assess changes within groups across time (pre-intervention, post-intervention, follow-up) in death distress as measured by The Death and Dying Distress Scale (DADDS) in the proof of concept project.
Time Frame: 6 months
|
Death and Dying Distress Scale (DADDS).
The DADDS is a validated measure of death anxiety in patients with advanced cancer.
The 15-item scale includes items about distress related to the dying process, running out of time, and the impact of one's death on loved ones.
The items are scored on a six-point Likert scale: 0 (not distressed) to 5 (extreme distress).
Moderate death anxiety is defined by Death and Dying Distress Scale scores between 25 and 46, and severe death anxiety is defined as scores >47.
|
6 months
|
|
Repeated measures will assess changes within groups across time (pre-intervention, post-intervention, follow-up) in death distress as measured by The Death and Dying Distress Scale (DADDS) in the pilot trial.
Time Frame: 6 months
|
Death and Dying Distress Scale (DADDS).80
The DADDS is a validated measure of death anxiety in patients with advanced cancer.80
The 15-item scale includes items about distress related to the dying process, running out of time, and the impact of one's death on loved ones.
The items are scored on a six-point Likert scale: 0 (not distressed) to 5 (extreme distress).
Moderate death anxiety is defined by Death and Dying Distress Scale scores between 25 and 46, and severe death anxiety is defined as scores >47.
|
6 months
|
|
Repeated measures will assess changes within groups across time (pre-intervention, post-intervention, follow-up) in attachment as measured by Experiences in Close Relationships Inventory (ECR-M-16) in the proof of concept project.
Time Frame: 6 months
|
Experience in Close Relationships Inventory (ECR-M16).
The ECR-M16 is a modified version of the 36- item ECR which has been validated for measuring attachment orientations to close others in patients with advanced cancer.
It comprises 16 items in two subscales (attachment anxiety and avoidance).
Respondents are asked to rate each item on a scale of 1-7: 1 (completely disagree) to 7 (completely agree).
|
6 months
|
|
Repeated measures will assess changes within groups across time (pre-intervention, post-intervention, follow-up) in attachment as measured by Experiences in Close Relationships Inventory (ECR-M-16) in the pilot trial
Time Frame: Post-randomization, 3, and 6 months after first assessment
|
Experience in Close Relationships Inventory (ECR-M16).
The ECR-M16 is a modified version of the 36- item ECR which has been validated for measuring attachment orientations to close others in patients with advanced cancer.
It comprises 16 items in two subscales (attachment anxiety and avoidance).
Respondents are asked to rate each item on a scale of 1-7: 1 (completely disagree) to 7 (completely agree).
|
Post-randomization, 3, and 6 months after first assessment
|
|
Repeated measures will assess changes within groups across time (pre-intervention, post-intervention, follow-up) in posttraumatic stress as measured by the PTSD Checklist for DSM-5 (PCL-5) in the proof of concept project
Time Frame: 6 months
|
PTSD Checklist for DSM-5 (PCL-5).
The PCL-5 is a 20-item assessment of PTSD symptoms which are concordant with the DSM-5 diagnostic items.
Reponses are answered on a 5-point Likert scale (0 = Not at all, 1= A little bit, 2 = Moderately, 3 = Quite a bit, 4 = Extremely).
Item scores are summed to yield a total score ranging from 0 to 80.
|
6 months
|
|
Repeated measures will assess changes within groups across time (pre-intervention, post-intervention, follow-up) in posttraumatic stress as measured by the PTSD Checklist for DSM-5 (PCL-5) in the pilot trial
Time Frame: 6 months
|
PTSD Checklist for DSM-5 (PCL-5).
The PCL-5 is a 20-item assessment of PTSD symptoms which are concordant with the DSM-5 diagnostic items.
Reponses are answered on a 5-point Likert scale (0 = Not at all, 1= A little bit, 2 = Moderately, 3 = Quite a bit, 4 = Extremely).
Item scores are summed to yield a total score ranging from 0 to 80.
|
6 months
|
|
Repeated measures will assess changes within groups across time (pre-intervention, post-intervention, follow-up) in substance use as measured by the Tobacco, Alcohol, Prescription medication and other Substance Use (TAPS) in the proof of concept project.
Time Frame: 6 months
|
The TAPS tool includes a screener and a brief assessment.
The TAPS-1 is a screener adapted from the National Institute on Drug Use quick screen with 4 items assessing frequency of use of tobacco, alcohol, prescription medication, and illicit substances (e.g., marijuana, cocaine).Any response other than "never" on the TAPS-1 indicates a positive screen, which leads to administration of the TAPS-2.
The TAPS-2 is a brief assessment adapted from the Alcohol, Smoking, and Substance Involvement Screening Tool (ASSIST)-Lite104 including 3-4 yes/no questions for each class of substances assessing level of use, dependence, and concern from others.
Cut-off for problematic substance use is 1+ and for substance use disorder is 2+.
|
6 months
|
|
Repeated measures will assess changes within groups across time (pre-intervention, post-intervention, follow-up) in substance use as measured by the Tobacco, Alcohol, Prescription medication and other Substance Use (TAPS) in the pilot trial
Time Frame: 6 months
|
The TAPS tool includes a screener and a brief assessment.
The TAPS-1 is a screener adapted from the National Institute on Drug Use quick screen with 4 items assessing frequency of use of tobacco, alcohol, prescription medication, and illicit substances (e.g., marijuana, cocaine).Any response other than "never" on the TAPS-1 indicates a positive screen, which leads to administration of the TAPS-2.
The TAPS-2 is a brief assessment adapted from the Alcohol, Smoking, and Substance Involvement Screening Tool (ASSIST)-Lite104 including 3-4 yes/no questions for each class of substances assessing level of use, dependence, and concern from others.
Cut-off for problematic substance use is 1+ and for substance use disorder is 2+.
|
6 months
|
|
Repeated measures will assess changes within groups across time (pre-intervention, post-intervention, follow-up) in clinical evaluation as measured by the Clinical Evaluation Questionnaire (CEQ) in the proof of concept project.
Time Frame: 6 months
|
Clinical Evaluation Questionnaire (CEQ).
The CEQ is a 7-item measure that was developed by the CALM team at Princess Margaret Cancer Centre to assess the extent to which individuals feel emotionally supported by clinical services in the domains relevant to CALM therapy.
The CEQ refers to the patients' experience of CALM therapy.
|
6 months
|
|
Repeated measures will assess changes within groups across time (pre-intervention, post-intervention, follow-up) in clinical evaluation as measured by the Clinical Evaluation Questionnaire (CEQ) in the pilot trial
Time Frame: 6 months
|
Clinical Evaluation Questionnaire (CEQ).
The CEQ is a 7-item measure that was developed by the CALM team at Princess Margaret Cancer Centre to assess the extent to which individuals feel emotionally supported by clinical services in the domains relevant to CALM therapy.
For intervention participants, the CEQ refers to the patients' experience of CALM therapy.
For TUC control participants, the CEQ refers to the patient's interactions with the health care team at their treating facility.
The CEQ is assessed only at 3 and 6 months.
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ashlee Loughan, PhD, Virginia Commonwealth University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MCC-21-18040
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.